StemRad(4599) Earnings Report: Operating Loss of 1,998 Million Yen Recorded

StemRad (4599) has released its latest financial results, detailing its current earnings performance. For the period, the company reported an operating loss of 1,998 million yen, an ordinary loss of 1,879 million yen, and a net loss of 1,851 million yen, with basic earnings per share at -29.63 yen. As a research-and-development-driven biopharmaceutical company, the results reflect ongoing investments in R&D and pipeline advancement.

Looking at the financial foundation and cash flow metrics, operating cash flow stood at -1,609 million yen, while investing cash flow was -3,207 million yen, resulting in a free cash flow of -4.82 billion yen. Meanwhile, cash and cash equivalents remained at 2.18 billion yen. The return on equity (ROE) was -0.369 and the return on assets (ROA) was -0.28, as market participants continue to monitor future clinical milestones and commercialization progress.